Large pharmaceutical firms are more land in Hyderabad as they give the impression of being to lock-in unused capital in actual property.
According to property brokers, residential and business land offers to the tune of Rs4,000-5,000 crore have been famous in Hyderabad.
Companies like Hetero, Aurobindo, Divi’s Lab and Dr Reddy’s have lately bought acres of land within the metropolis.
Other corporations that maintain land banks embrace Morepen Laboratories and Cipla.
“It is good diversification away from investing in the stock market,” said a senior executive at a brokerage firm. “A lot of Hyderabad-based firms prefer investing in land more than any other asset class. They prefer to hold the land for 10-20 years to encash it to get 6x returns.”
The Indian pharma trade has proven a double-digit development of round 15% in 2021, led by the expansion of Covid-19 merchandise within the final one yr, as in opposition to a single digit development of three% proven in 2020, in keeping with Indian pharmaceutical market analysis firm Pharmasofttech AWACS Pvt Ltd.
The land shopping for spree has led to a pointy rise in land costs too.
“There is a high demand for agricultural land and the prices have gone up by 40-80% in the last two years, while residential plots in the core areas have seen upwards of 50% price appreciation,” said Vineet Surana, founder of MD Property Solutions. “Even the government auction has seen interest from pharmaceutical companies.”
The metropolis has additionally seen big-ticket lease transactions for establishing analysis and improvement items from pharmaceutical firms trying to broaden their enterprise operations.
Some world corporations which have arrange or need to broaden their R&D items in Hyderabad embrace Aurobindo, Laurus, Sai Life and Syngebe.
“Hyderabad has become synonymous with pharma as Bangalore is with the IT sector,” said Jasmeet Chhabra, managing partner, CerestraAdvisors. “We anticipate a huge demand for pharma real estate and are currently developing 2.5 million sq ft of world-class research infrastructure within Genome Valley to cater to the growing demand.”
Hyderabad has emerged as the most important pharma and life sciences hub in India with its built-in ecosystem from analysis to manufacturing coupled with a big pool of expertise and government-led infrastructure improvement throughout Genome Valley for R&D, Pharmacity for manufacturing and Medical Devices Park for ancillaries.
“Hyderabad had seen strong recovery gains in 2020 and maintained its streak in 2021 as well,” stated Arpit Mehrotra, managing director for workplace providers (south India) at Colliers. “The city has emerged as the preferred destination for major R&D-focused companies. We have a strong demand pipeline for leased life sciences R&D facilities in Hyderabad.”
